Farmacogenetica in de psychiatrie; de huidige status quo

Translated title of the contribution: Current status quo on Pharmacogenetics in psychiatry

Roos van Westrhenen*, Tom K. Birkenhäger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademic


Background Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant. Aim To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis. Method To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry. Results The Dutch Association for Psychiatrists (NVvP) authorized a guideline 'Pharmacogenetics in Psychiatry' that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed. Conclusion For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants.
Translated title of the contributionCurrent status quo on Pharmacogenetics in psychiatry
Original languageDutch
Pages (from-to)312-316
Number of pages5
JournalTijdschrift voor Psychiatrie
Issue number5
Publication statusPublished - 10 May 2022


  • Cytochrome P-450 CYP2D6/genetics
  • Humans
  • Pharmacogenetics
  • Psychiatry
  • Psychotropic Drugs


Dive into the research topics of 'Current status quo on Pharmacogenetics in psychiatry'. Together they form a unique fingerprint.

Cite this